Jianxin Sun1, James K Liao. 1. Vascular Medicine Research Unit, Brigham & Women's Hospital and Harvard Medical School, Boston, Mass, USA.
Abstract
OBJECTIVE: A specific inhibitor of heat shock protein 90 (Hsp90), 17-AAG, has been shown to inhibit tumor growth through cell cycle arrest, differentiation, or apoptosis. Because angiogenesis is important for tumor growth, we hypothesize that inhibition of angiogenesis by 17-AAG may mediate some of its antitumor effects. METHODS AND RESULTS: Because protein kinase Akt and endothelial nitric oxide synthase (eNOS) are critical for angiogenesis, we studied the effects of 17-AAG on the phosphorylation and expression of Akt and eNOS in human umbilical vein endothelial cells. In a concentration- and time-dependent manner, inhibition of Hsp90 by 17-AAG decreased Akt and eNOS expression by 74% and 81%, respectively. Inhibition of eNOS expression by 17-AAG occurred at the transcriptional level as determined by eNOS promoter activity and nuclear run-on assay. Furthermore, treatment with 17-AAG decreased basal and vascular endothelial growth factor-stimulated Akt and eNOS phosphorylation. This corresponded with decreased NO production and inhibition of endothelial cell migration and angiogenesis. The anti-angiogenic effect of 17-AAG was partially reversed by the NO donor, SNAP. CONCLUSIONS: These findings indicate that Hsp90 is important not only for Akt and eNOS phosphorylation but also for eNOS gene transcription and suggests that Hsp90 may be a novel target for anti-angiogenic therapy.
OBJECTIVE: A specific inhibitor of heat shock protein 90 (Hsp90), 17-AAG, has been shown to inhibit tumor growth through cell cycle arrest, differentiation, or apoptosis. Because angiogenesis is important for tumor growth, we hypothesize that inhibition of angiogenesis by 17-AAG may mediate some of its antitumor effects. METHODS AND RESULTS: Because protein kinase Akt and endothelial nitric oxide synthase (eNOS) are critical for angiogenesis, we studied the effects of 17-AAG on the phosphorylation and expression of Akt and eNOS in human umbilical vein endothelial cells. In a concentration- and time-dependent manner, inhibition of Hsp90 by 17-AAG decreased Akt and eNOS expression by 74% and 81%, respectively. Inhibition of eNOS expression by 17-AAG occurred at the transcriptional level as determined by eNOS promoter activity and nuclear run-on assay. Furthermore, treatment with 17-AAG decreased basal and vascular endothelial growth factor-stimulated Akt and eNOS phosphorylation. This corresponded with decreased NO production and inhibition of endothelial cell migration and angiogenesis. The anti-angiogenic effect of 17-AAG was partially reversed by the NO donor, SNAP. CONCLUSIONS: These findings indicate that Hsp90 is important not only for Akt and eNOS phosphorylation but also for eNOS gene transcription and suggests that Hsp90 may be a novel target for anti-angiogenic therapy.
Authors: Nicola J Mabjeesh; Dawn E Post; Margaret T Willard; Balveen Kaur; Erwin G Van Meir; Jonathan W Simons; Hua Zhong Journal: Cancer Res Date: 2002-05-01 Impact factor: 12.701
Authors: Andrea D Basso; David B Solit; Gabriela Chiosis; Banabihari Giri; Philip Tsichlis; Neal Rosen Journal: J Biol Chem Date: 2002-08-09 Impact factor: 5.157
Authors: Suresh I S Rattan; Ricardo A Fernandes; Dino Demirovic; Barbara Dymek; Cristovao F Lima Journal: Dose Response Date: 2008-09-10 Impact factor: 2.658
Authors: Vienna E Brunt; Karen M Weidenfeld-Needham; Lindan N Comrada; Michael A Francisco; Taylor M Eymann; Christopher T Minson Journal: Temperature (Austin) Date: 2019-05-16